NASDAQ:IPXL - Impax Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$18.30
Today's Range$17.40 - $18.95
52-Week Range$13.05 - $25.70
Volume3.04 million shs
Average Volume945,265 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment engages in the development, sale, and distribution of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1995 and is headquartered in Hayward, California.

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:IPXL
CUSIP45256B10
Phone510-476-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1,257
OptionableOptionable

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories (NASDAQ:IPXL) posted its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to the consensus estimate of $208.38 million. The company's revenue was down 9.4% on a year-over-year basis. During the same quarter last year, the business earned $0.37 earnings per share. View Impax Laboratories' Earnings History.

What price target have analysts set for IPXL?

7 analysts have issued 12-month target prices for Impax Laboratories' shares. Their forecasts range from $19.00 to $35.00. On average, they anticipate Impax Laboratories' share price to reach $23.7143 in the next year. View Analyst Price Targets for Impax Laboratories.

What is the consensus analysts' recommendation for Impax Laboratories?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impax Laboratories in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Impax Laboratories.

Has Impax Laboratories been receiving favorable news coverage?

Press coverage about IPXL stock has trended very positive on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Impax Laboratories earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:
  • Mr. Bryan M. Reasons, Sr. VP of Fin. & CFO (Age 51)
  • Mr. Mark A. Schlossberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
  • Mr. Michael J. Nestor, Pres of Impax Specialty Pharma Division (Age 65)
  • Mr. Douglas S. Boothe, Pres of Impax Generics Division (Age 54)
  • Mr. Paul M. Bisaro, CEO, Pres & Director (Age 57)

How do I buy shares of Impax Laboratories?

Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' official website?

The official website for Impax Laboratories is http://www.impaxlabs.com.

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]


MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  537 (Vote Underperform)
Total Votes:  913
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel